Strand Life Sciences StrandAdvantage Genomic Profiling Service

Strand Genomics said this week that it will introduce its expanded StrandAdvantage pan-cancer genomic profiling service at the American Society of Clinical Oncology meeting in Chicago next week. The new version of StrandAdvantage will include a panel that examines 152 genes and pathways known to be impacted by existing targeted cancer therapies plus additional chemotherapeutic toxicity and resistance data. The service provides oncologists with clinically actionable results beginning with a report on eight "standard-of-care" genes delivered to the oncologist within eight days. A full report is provided within 15 days that covers all major gene variants and pathways known to be impacted by existing targeted therapies.